Updates are available Correction dated 2022-07-13
Click to view Correction: https://doi.org/10.1186/s13059-022-02724-9
-
Authors
Khaliq, Ateeq M.
Erdogan, Cihat
Kurt, Zeyneb
Turgut, Sultan Sevgi
Grunvald, Miles W.
Rand, Tim
Khare, Sonal
Borgia, Jeffrey A.
Hayden, Dana M.
Pappas, Sam G.
Govekar, Henry R.
Kam, Audrey E.
Reiser, Jochen
Turaga, Kiran
Radovich, Milan
Zang, Yong
Qiu, Yingjie
Liu, Yunlong
Fishel, Melissa L.
Turk, Anita
Gupta, Vineet
Al-Sabti, Ram
Subramanian, Janakiraman
Kuzel, Timothy M.
Sadanandam, Anguraj
Waldron, Levi
Hussain, Arif
Saleem, Mohammad
El-Rayes, Bassel
Salahudeen, Ameen A.
Masood, Ashiq http://orcid.org/0000-0002-1848-1178
- License Information
-
More Information
Article History
Received: 15 December 2021
Accepted: 21 April 2022
First Online: 11 May 2022
Change Date: 13 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13059-022-02724-9
Declarations
:
: The study was approved by Rush University Institutional review board (No. 15021301). All study participants provided written informed consent. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and in accordance with the Helsinki Declaration.
: Not applicable.
: Ashiq Masood and Jeffrey A. Borgia received research funding from Tempus lab. Anjuraj Sadanandam receives research funding from Bristol-Myers Squibb; Merck KGaA, Pierre Fabre. Furthermore, Anjuraj Sadanandam. holds patent PCT/IB2013/060416, “Colorectal cancer classification with differential prognosis and personalized therapeutic responses,” and patent number 2011213.2 “Prognostic and Treatment Response Predictive Method.”
